Eli Lilly Increases Sales Forecast Amid High Demand for Zepbound

Indianapolis, Thursday, 7 August 2025.
Eli Lilly has boosted its annual profit forecasts, driven by a surge in demand for its weight-loss drug Zepbound, highlighting a growing market focus on weight management solutions.